NBI and MRI to guide radiation planning for one-sided nose cancer
Part of Cancer clinical trials.
This trial tests whether combining a special scope (NBI) with MRI scans can help doctors better target radiation therapy for a specific type of nose/throat cancer that affects only one side. It aims to make treatment more precise and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be able to carry out daily activities with minimal help (ECOG score 0, 1, or 2).
- You must have a confirmed diagnosis of nasopharyngeal carcinoma (a type of nose/throat cancer).
- The cancer must be mainly on one side of your nasopharynx (eccentric), with no cancer on the other side.
- You must have had an MRI and a special scope exam (NBI) before starting treatment.
- You must be healthy enough to receive radiation therapy without any major risks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a simpler way to plan radiation for a type of throat cancer called nasopharyngeal carcinoma. It uses a standard method to outline the area needing treatment, which may make planning faster and more consistent.
This trial tests a new way to shape the radiation field for nasopharyngeal cancer that has spread into the nasal cavity. The goal is to reduce radiation to the nose while still effectively treating the cancer.
This trial tests whether intense radiation therapy (IMRT) alone is effective for people with stage IB nasopharyngeal carcinoma (a type of head and neck cancer) that has not spread to lower lymph nodes or formed large, matted nodes. If you qualify, you would receive targeted radiation without chemotherapy.
This trial tests a new way to plan radiation treatment for nasopharyngeal cancer, where the target area is tailored to each patient's tumor spread. It aims to improve effectiveness while reducing side effects.
This trial tests whether adjusting chemotherapy based on tumor markers (EBV-DNA) and MRI scans can improve outcomes and reduce side effects for people with nasopharyngeal cancer. If you have stage II or III disease, this study might help guide your treatment more precisely.
This study uses special MRI images (and computer “radiomics” scores) to better understand nasopharyngeal cancer. The goal is to help doctors choose the most appropriate treatment for people with newly diagnosed cancer.
Hear when a new Nasopharyngeal Carcinoma by AJCC V8 Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.